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During the transition period, 3 wk before to 3 wk after calving, dairy cows experience a 
variety of sudden hormonal and metabolic shifts that could result in metabolic disorders or 
diseases, which can be detrimental to the productive life and longevity of the cow.  Cows 
undergo a negative energy balance, where they cannot consume enough feed to meet their energy 
requirements.  To make up this deficit, cows mobilize adipose tissue in the form of non-esterified 
fatty acids (NEFA) which are transported to the liver and are either used for fuel or stored as 
triglycerides.  High levels of circulating NEFA can lead to endoplasmic reticulum (ER) stress, 
which is linked to inflammation.  This low-grade inflammation can compromise cell function.  
To mitigate this inflammation, sodium salicylate, a non-steroidal anti-inflammatory drug 
(NSAID), was given to mature (3+ parity) cows for 7 d after parturition via their drinking water.  
Blood was collected daily and a glucose turnover assay was performed.  Liver, muscle, and 
adipose tissue was collected on d 7.  Overall, it appeared that SS increased insulin sensitivity and 
depressed gluconeogenesis post-transcriptionally.  Multiple in vitro studies were performed on 
immortalized bovine mammary epithelium (MAC-T) cells to determine the action of SS when 
ER stress was induced with palmitate (PALM).  Treatment with SS did not mitigate, and in some 
cases exacerbated, the ER stress response.  The addition of bovine serum albumin (BSA), a 
common component of cell culture media, may alter reactive oxygen species (ROS) 
measurements due to its antioxidant property.  Overall, SS seems to alter metabolic processes 
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Chapter 1 - Literature Review 
The transition period is one of the most problematic periods that a dairy cow will ever 
undergo.  During this period, defined as 3 wk before to 3 wk after calving (Gummer 1995), the 
cow experiences endocrine changes due to calving and metabolic changes due to a sudden 
increase in energy demand to synthesize milk, as well as being switched to a high-energy 
lactating cow diet (Drackley, 1999; Ingvartsen, 2006; Mulligan and Doherty, 2008).  These 
sudden and drastic changes can result in disorders or diseases that can be detrimental to the 
productive life and longevity of the cow.  Goff (2008) stated that cows need a strong immune 
system, normal calcium levels, and must suffer no significant decreases in feed intake to have a 
successful transition period.  If these three physiological statuses can be maintained, a cow can 
have a relatively smooth transition period.  Likewise, a failure of any one of these 3 aspects can 
put a cow at risk for succumbing to 1 or many disorders. 
The profitability of a cow during her lactation is determined by how successful her 
transition period is (Drackley, 1999).  According to Leblanc (2010), it is estimated that 30-50% 
of dairy cows will experience a metabolic disorder or infection during the transition period.  
Transitional disorders can cost between $224 and $494 per cow per case due to milk loss, 
veterinary fees, cost of treatment, extra labor to tend to the sick cow, and delays in rebreeding 
(Guard, 2008).  The high prevalence coupled with the high cost of treatment for transition 
disorders has made it imperative to identify methods to mitigate these disorders.  This review 
will discuss metabolic challenges that cows undergo and their link to systemic inflammation, and 
the use of sodium salicylate, a non-steroidal anti-inflammatory drug, as a possible method to 
moderate this chronic inflammation as a method for increasing transition period success. 
 Metabolic Changes and Transition Disorders 
During the 3 weeks postpartum, cows are at a high risk of succumbing to 1 or more 
disorders related to the metabolic shifts that cow is experiencing.  The most common disorders 
include ketosis, milk fever, fatty liver, rumen acidosis, displaced abomasum, metritis, and 
mastitis (Ingvartsen, 2006; Mulligan and Doherty, 2008).  These disorders are all interconnected, 
so that a cow suffering from one disorder has a higher chance of succumbing to another disorder.  
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Milk fever is known as a ‘gateway disease’ due to its high correlation to other metabolic 
disorders (Mulligan and Doherty, 2008), while fatty liver is considered a secondary disease of 
other disorders that inhibit feed intake (Ingvartsen, 2006).     
Cows experience a large increase in energy demand after parturition due to the onset of 
lactation.  Often, the cow is unable to consume enough energy to meet these demands and enters 
a state known as negative energy balance (NEB).  This NEB can be exacerbated since cows 
endure an almost 20% decrease in voluntary DMI around parturition as well as undergoing a 
decrease in plasma glucose concentrations (Grummer, 1995).  To compensate for the energy 
shortage, the cow will mobilize fatty acids from adipose tissue.  These fatty acids are released 
into plasma as non-esterified fatty acids (NEFA).  In the liver, NEFA can be taken up and 
completely or partially oxidized to provide energy to the animal or be converted to triglycerides 
(TG).  Since the majority of the circulating glucose is being diverted to the mammary gland, the 
energy that these fat-derived fuels supply is crucial for meeting the energy demand of the rest of 
the body.    
Partial oxidation of NEFA results in the creation of ketone bodies, which are released 
from the liver and used by peripheral tissues as a source of energy.  Ketosis occurs when there 
are relatively high levels of ketones in the blood coupled with low circulating glucose 
(Ingvartsen, 2006).  In the United States, 2-20% of cows experience clinical ketosis during the 
first month of lactation, while the incidence of those undergoing subclinical ketosis is as high as 
34% (Ingvartsen, 2006).  Over-conditioned cows that have large adipose tissue deposits are at a 
much higher risk of ketosis, as are cows that suffered ketosis in a previous lactation (Bobe et al., 
2004; Ingvartsen, 2006). 
When the uptake of NEFA into the liver exceeds the amount of NEFA that the liver can 
completely or partially oxidize, NEFA will be converted to triglycerides.  These triglycerides 
will accumulate in the liver and, in large quantities, can impair hepatic function and may hinder 
glucose synthesis (Bobe et al., 2004).  This accumulation of TG in the liver results in what is 
known as fatty liver syndrome and nearly 50% of cows experience some degree of this during 
the transition period.  Obese cows, which have large stores of adipose tissue, are at a much 
higher risk for developing fatty liver because they have an increased mobilization of NEFA from 
adipose tissue and greater depression of feed intake at calving.  This can lead to a more severe 
negative energy balance and demand even more NEFA to be mobilized (Bobe et al., 2004).  
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Fatty liver and ketosis are highly correlated, meaning that a cow with fatty liver is at a much 
higher risk of ketosis and cows suffering from ketosis are at a higher risk of having a fatty liver 
(Bobe et al., 2004).  Fatty liver can compromise immune function by hindering the release of 
inflammatory mediators such as leukocytes, lymphocytes, and neutrophils and increases 
circulating proinflammatory cytokines (Bobe et al., 2004).  This can render a cow unable to fight 
off infection such as mastitis. 
There are a plethora of other physiological shifts that occur at parturition that have the 
potential to induce a transition disorder.  Insulin resistance occurs when cells are unable to 
respond to the normal actions of insulin.  High levels of circulating NEFA have been linked to 
insulin resistance, indicating that transition period cows may be undergoing a state of insulin 
resistance (Hayirli, 2006).  Reducing the effectiveness of insulin seems to facilitate the funneling 
of available glucose to the mammary gland to be used as energy for milk synthesis (Giesy et al., 
2012).  Approximately 85% of the total glucose supply is diverted to the mammary gland 
(Sordillo et al., 2009).   
Cows may also experience hypocalcemia and, in severe cases, milk fever due to the 
mobilization of calcium to meet the demands for milk production (Leblanc, 2010).  On top of 
coping with these drastic metabolic changes, cows experience immunosuppression (Goff, 2008; 
Leblanc, 2010).  There can be a 25-40% decline in neutrophil and lymphocyte function and if a 
cow suffers from a metabolic disease, this can increase to as high as 60-80% loss of immune 
function (Goff, 2008). 
At the onset of lactation, there is a struggle to meet the energy demand of lactation during 
a period of immunosuppression and a failure to meet this demand can result in metabolic 
disorders that will exacerbate the cow’s already weakened immune system.  These challenges 
predispose her to other disorders that can have large negative economic impacts, hinder whole-
lactation productivity, and reduce cow longevity in the herd. 
 Systemic Inflammation and its Relationship to the Transition Cow 
The dairy cow possesses a robust immune system that helps restore order after being 
invaded by pathogens or experiencing harmful stimuli.  While the immune system fights 
whatever stimuli activated a response, it also has to control the extent of the response so as to not 
damage surrounding tissue and cells.  The immune system is comprised of innate and acquired 
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immunity.  Innate immunity provides the initial, non-specific response to a pathogen.  
Components that are involved in the innate response include leukocytes, cytokines, eicosanoids, 
and non-immune cells such as epithelial and endothelial cells (Sordillo et al., 2009).  Acquired 
immunity is a more specific response that is elicited when an infectious agent successfully 
evades the innate immune response.  If the animal encounters that pathogen again, 
immunological memory will render a heightened state of immune activity that is faster and 
stronger than what occurred during the first encounter (Janeway et al., 2005). 
Inflammation can be classified as either acute or chronic.  Acute inflammation is 
characterized by vasodilation, release of eicosanoids and cytokines, and clinical symptoms that 
include redness, swelling, heat, and pain at the site of infection.  This acute inflammation is a 
positive response since it quickly eliminates the offending pathogen and does not usually result 
in the damage of nearby tissues and cells.  Conversely, chronic or low-grade inflammation can 
be detrimental to the normal function of the animal and damage tissues and cells.  This 
inflammation is initiated by excess or severe shortage of nutrients and has been dubbed by some 
as meta-inflammation (Hotamisligil, 2006). 
 Meta-inflammation in the Transition Dairy Cow 
The regulatory pathways of immune and metabolic functions of an organism are closely 
related.  This could be because the functional units that control the immune and metabolic 
functions came from common ancestral structures (Hotamisligil, 2006).  In fact, the metabolic 
and immune cells are close to each other in the liver and in adipose depots (Hotamisligil, 2006).  
Chronic inflammation was first linked with obesity and type 2 diabetes with the discovery that 
tumor necrosis factor-α (TNFα) was overexpressed in obese mice (Hotamisligil et al., 1993).  
TNFα is a proinflammatory cytokine that also promotes insulin resistance.  This illustrated that 
an inflammatory response can alter metabolic function, in this case insulin action, during obesity. 
Transition cows possess characteristics similar to type-2 diabetes, including a state of 
low-grade inflammation right after parturition (Humblet et al., 2006), mobilization of fat stores, 
and elevated NEFA levels (Contreras and Sordillo, 2011).  As previously alluded to, obese cows 
are at a higher risk of contracting a metabolic disorder because of the elevated NEFA levels.  
This is similar in humans, where obese people have a much higher chance of succumbing to type 
2 diabetes (Hotamisligil, 2010). 
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 Lipids and the Inflammatory Response 
Though the true mechanism for how lipids cause an inflammatory response is not known, 
there are several possible pathways by which lipids could initiate a response.  When NEFA enter 
the cell and are not used for energy, they can be transported to the ER or the Golgi apparatus 
where they can attach to proteins and be used in the cell membrane (Contreras and Sordillo, 
2011).  Once in the cell, fatty acids can bind to receptors and regulate gene expression.  One 
example of this is the ability of lipids to regulate peroxisome proliferator-activated receptors 
(PPAR).  PPAR modulate the inflammatory response in many cells such as adipocytes 
(Contreras and Sordillo, 2011).  Another example of lipids influencing receptor binding is the 
activation of Toll-like receptors (TLR), especially TLR4.  TLR4 activation can lead to an 
inflammatory response as well as an upregulation of proinflammatory cytokines (Sordillo et al., 
2009; Contreras and Sordillo, 2011; Baker et al., 2011). 
Another way lipids can orchestrate an inflammatory response is through the biosynthesis 
of lipid mediators such as spingolipids, ceramides, and eicosanoids (Hannun and Obeid, 2008; 
Sordillo et al., 2009).  Eicosanoids are regulators of inflammatory response whose precursors 
include thromboxanes, prostacyclins and prostaglandins.  These precursors come from the 
polyunsaturated fatty acids (PUFA) that are metabolized either through the cyclooxygenase 
(COX) or lipooxygenase (LOX) pathways (Sordillo et al., 2009).  There are two isoforms of 
COX; COX1 is expressed in most tissues and synthesize low levels of prostaglandins and COX2 
is associated with the biosynthesis of proinflammatory mediators (Amann and Peskar, 2002; 
Sordillo et al., 2009; Contreras and Sordillo, 2011). 
A third way lipids can initiate an inflammatory response is by inducing endoplasmic 
reticulum (ER) stress.  The ER is responsible for many activities in the cell including protein 
folding and storage of calcium.  ER stress can be caused by myriad physiological actions 
including high levels of fatty acids, much like what occurs in a transition cow.  ER stress leads to 
a protein folding deficit, where the protein folding capacity of the ER is at maximum capacity or 
the folding process is interrupted and cannot meet the demands of the cell.  This can cause an 
accumulation of unfolded or misfolded proteins to accumulate in the cell (Zhang and Kaufman, 
2008; Hotamisligil 2010).  In order to cope with this stress, the accumulation of these misfolded 
proteins initiates the unfolded protein response (UPR).  The main objective of the UPR is cell 
survival; the UPR works to restore the ER to homeostasis.  In the event that the UPR fails to 
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return the ER to homeostasis, the UPR will initiate apoptosis to protect the host from the large 
amount of misfolded proteins (Zhang and Kaufman, 2008; Hotamisligil, 2010; Tabas and Ron, 
2011). 
The UPR cascade has three starting points, which include inositol-requiring 1α (IRE1), 
double-stranded RNA-dependent protein kinase (PKR)- like ER kinase (PERK), and activating 
transcription factor 6 (ATF6; Zhang and Kaufman, 2008).  During normal ER function, these 
sensors are inactive due to the attachment of immunoglobulin-heavy-chain-binding protein (BiP 
or GRP78).  BiP has a high affinity for misfolded and unfolded proteins, so when there is a large 
build-up of these, BiP will detach from the three arms and attach to the misfolded proteins, thus 
activating the UPR (Hotamisligil, 2010). 
 Once BiP is detached, PERK is phosphorylated, allowing it to phosphorylate eukaryotic 
initiation factor 2α (eIF2α).  This phosphorylation inhibits the synthesis of new proteins in an 
attempt to slow down the buildup of the misfolded and unfolded proteins (Zhang and Kaufman, 
2008).  The phosphorylation of eIF2α also allows the translation of activating transcription factor 
4 (ATF4), which then enters the nucleus of the cell and upregluates target genes involved with 
amino acid biosynthesis, oxidative stress response and apoptosis (Hotamisligil, 2010). 
When the IRE1 branch is activated, IRE1 auto-phosphorylates.  IRE1 then splices X-box-
binding protein-1 (XBP-1) into its active form, referred to here as XBP-1s.  XBP-1s is a key 
factor for transcription during ER stress.  XBP-1s travels to the nucleus where it induces 
transcription of genes that code for ER chaperones and enzymes involved with protein folding, 
maturation, and export (Zhang and Kaufman, 2008).  ATF6 follows a similar pathway to IRE1 
when activated.  ATF6 migrates to the Golgi apparatus and is cleaved by site-1 protease (S1P) 
and S2P.  The remaining fragment of ATF6 then goes to the nucleus and follows the same 
pathway as XBP-1s (Hotamisligil, 2010). 
If these three branches of the UPR are unable to revert the ER back to homeostasis 
through the alteration of cell transcription, the UPR will then initiate apoptosis, which is mainly 
mediated by CCAAT/enhancer-binding protein homologous protein (CHOP).  Initiation of 
apoptosis is a defense mechanism to protect the host from cells that are functionally 
compromised.  Cells that are exposed to severe and chronic stress signals, such as inflammatory 
cytokines and high fatty acid or glucose levels, are often subjected to apoptosis. 
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The UPR is linked with the nuclear factor-κB (NF-κB) and JUN N-terminal kinase (JNK) 
inflammatory pathways.  The branches of UPR can directly initiate an inflammatory response or 
act indirectly through accumulation of reactive oxygen species (ROS).  As previously mentioned, 
the ER stores a large amount of calcium.  When there is an accumulation of misfolded and 
unfolded proteins, calcium begins to leak out of the ER and into the mitochondria.  Calcium 
disrupts normal functions by depolarizing the mitochondrial membrane and disrupts the electron 
transport chain (Zhang and Kaufman, 2008).  This leads to an increase of ROS production, and a 
subsequent onset of oxidative stress.  High levels of ROS will initiate the NF-κB and JNK 
pathways since ROS are important mediators in these pathways. 
When at rest, NF-κB is bound by inhibitor of κB (IκB), which does not allow NF-κB to 
leave the cytosol (Baker et al., 2011).  The NF-κB pathway can be initiated either by the UPR 
response, high levels of inflammatory cytokines, or TLR activation.  Upon initiation, the 
inhibitor of κB kinase (IKK) complex is activated and will phosphorylate IκB molecules, thereby 
releasing NF-κB (Zhang and Kaufman, 2008).  Once freed, NF-κB will upregulate specific genes 
that are involved with cell proliferation and release cytokines that will activate an immune 
response (Baker et al., 2011).   
The JNK pathway is largely initiated by the IRE1 branch of the UPR response.  Once 
IRE1 is activated, it recruits TNF-α-receptor-associated factor 2 (TRAF2), which then recruits 
and activates JNK (Zhang and Kaufman, 2008).  Once activated, JNK phosphorylates serine 
residues in insulin-receptor substrate 1 (IRS1).  This inhibits the phosphorylation of IRS-1 
tyrosine residues, which limit IRS-1 function and can lead to insulin resistance (Zhang and 
Kaufman, 2008).  Ozcan and colleagues (2004) demonstrated this when they induced ER stress 
in mouse hepatocytes.  The liver cells that were stressed had increased levels of serine-
phosphorylated IRS-1.  When cells were treated with a synthetic inhibitor of JNK, serine-
phosphorylation of IRS-1 was reversed. 
 Systemic Inflammation Involvement in Transition Disorders 
There are many ways in which different transition cow disorders can initiate an 
inflammatory response.  The infectious diseases, such as metritis and mastitis, directly initiate an 
acute response to combat the invading pathogens.  Elevated levels of lipolysis in the adipose 
tissue will increase the circulating NEFA concentration.  High levels of fatty acids can induce 
ER stress, which in turn can initiate the NF-κB and JNK inflammatory pathways and lead to 
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systemic inflammation and insulin resistance.  High amounts of fatty acids can also activate TLR 
receptors and COX pathways, leading to a release of proinflammatory cytokines, which can also 
initiate ER stress and exacerbate inflammation. 
During the transition period, cows can be experiencing symptoms similar to type-2 
diabetes due to the hallmark insulin resistance, high concentrations of circulating NEFA, and 
resulting chronic inflammation.  Unlike type 2 diabetes however, cows also experience low 
blood glucose (Grummer, 1995).  This inflammation will produce inflammatory cytokines, such 
as TNFα, which can then in turn cause ER stress, creating a vicious cycle that can easily spin out 
of control and damage the host cells through excessive production of ROS, as well as the 
cytokines themselves doing damage when they are circulating in large quantities. 
 Use of Non-Steroidal Anti-Inflammatory Drugs to Mitigate Systemic 
Inflammation 
There are many management schemes to mitigate adipose mobilization to limit NEFA 
release that can be employed on dairy farms.  These range from using weight management of dry 
cows, to a gradual step up from a low energy to a high energy diet to a blanket treatment of all 
fresh cows with glucose precursors for a few days after calving.  All of these have varying 
degrees of success depending of the farm and implementation of the strategy.   
Given that researchers have discovered chronic inflammation plays a role in metabolic 
disturbances, a different approach to achieving a smooth transition period could be mitigating the 
inflammation itself.  If proinflammatory cytokine production could be limited, there would be 
less stimulation of ER stress and, in turn, less ROS production and less cell damage regardless of 
the amount of circulating NEFA.  This may also alleviate metabolic dysfunction since 
inflammation has been linked to insulin resistance and to compromised cell function. 
Non-steroidal anti-inflammatory drugs (NSAIDs) can be used to block endogenous 
inflammation.  NSAIDs are classified into groups based on their chemical structure or mode of 
action.  The drugs discussed in this review are aspirin and sodium salicylate (SS), which are 
found in the salicylate group of NSAIDs.   
 Actions of Sodium Salicylate 
Aspirin and SS, though in the same class, vary slightly in structure and function.  Aspirin 
contains an acetyl group, and when consumed, 50% of aspirin is almost immediately de-
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acetylated to salicylic acid (Amann and Peskar, 2002).  Aspirin is sometimes termed as a 
‘bifunctional drug’ because the acetyl group and the salicylic acid impact different pathways, 
essentially acting like two drugs in one (Rainsford, 2004).  In contrast, SS is a salt form of 
salicylic acid and does not contain an acetyl group. 
Sodium salicylate has a myriad of effects including being anti-inflammatory, antipyretic, 
and an analgesic.  There has been a wide variety of research done with SS to determine its 
mechanistic actions; however, there are many conflicting reports (Amann and Peskar, 2002). 
 COX-1 and COX-2 Inhibition 
Arachidonic acid is converted to prostaglandin by COX enzymes (Amann and Peskar, 
2002).  Arachidonic acid is derived from dietary sources of linoleic acid (C18:2; Rainsford, 
2004).  Prostaglandins are precursors to eicosanoids, which are involved in the inflammatory 
response.  Aspirin is an effective COX inhibitor because it carries an acetyl group that is released 
after ingestion and binds to a serine at the active site of the COX enzyme (Roth et al., 1975; 
Vane, 1994).  This blocks the active site, impeding the binding of arachidonic acid, and therefore 
irreversibly inhibiting prostaglandin synthesis and the subsequent inflammatory response 
(Amann and Peskar, 2002).  Sodium salicylate does not possess the acetyl group required to 
block the active site on the COX enzyme, making SS a weak COX inhibitor (Kopp and Ghosh, 
1994).  This was confirmed by Smith and others (1975), who found that aspirin, but not SS, 
reduced the rat foot swelling induced by carrageenan when arachidonic acid (an inflammatory 
precursor via the COX pathway) was concurrently administered.   The anti-inflammatory effects 
of SS must therefore be due to SS altering a different inflammatory pathway. 
Aspirin and SS, after being consumed, are converted to salicylic acid after the loss of 
either the acetyl or sodium group.  It is believed that salicylic acid is responsible for the majority 
of the anti-inflammatory effects exhibited by both drugs.  Whittle and colleagues (1980) 
demonstrated that aspirin and SS have similar anti-inflammatory potencies by indicating that the 
dose to reduce carrageenan-induced rat paw edema by 50% (ED50) for aspirin was 130 mg/kg 
and 140 mg/kg for SS.  Since the only thing aspirin and SS have in common structurally is the 
salicylic acid, this finding supports the belief that salicylic acid is responsible for the anti-
inflammatory effects demonstrated by these drugs. 
 Uncoupling of Oxidative Phosphorylation 
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Salicylate, but not aspirin, has been shown to activate adenosine monophosphate-
activated protein kinase (AMPK) in human embryonic kidney cells (Hawley et al., 2012).  When 
activated, AMPK switches off adenosine triphosphate (ATP) consuming processes and turns on 
ATP-generating pathways (catabolism).  Activation of AMPK usually occurs when ATP 
synthesis in the mitochondria is inhibited, which leads to increased levels of AMP and ADP 
(Smith and Smith, 1966; Hawley et al., 2012).  There is evidence that salicylate impairs the 
integrity and respiration function of mitochondria; therefore, it is possible that SS may also alter 
mitochondrial ATP synthesis by altering oxidative phosphorylation (Chung et al, 2003; Battaglia 
et al., 2005).  Cronstein and colleagues (1994) demonstrated that SS diminishes intracellular 
ATP in human umbilical vein endothelial cells (HUVEC).  This decrease in ATP formation then 
induced the release of adenosine into the extracellular fluid.  Cronstein and others (1999) 
speculated that uncoupling of oxidative phosphorylation could enhance ATP catabolism, thus 
releasing adenine nucleotides which are converted to adenosine extracellularly.  Adenosine is an 
anti-inflammatory agent, so it is thought that this adenosine pathway could be responsible, at 
least in part, for the anti-inflammatory effects exhibited by SS (Amann and Peskar, 2002).   
 Inhibition of the NF-κB Pathway 
As reported previously, NF-κB is an important transcription factor involved with the 
inflammatory response.  In its inactive state, NF-κB resides in the cytoplasm bound to IκB.  
Activation of NF-κB occurs when IKK, made up of IKK-α and IKK-β, phosphorylate IκB, which 
then releases NF-κB.  
Kopp and Ghosh (1994) found that SS inhibited NF-κB activation.  Further investigation 
revealed that SS prevented the release of NF-κB from IκB by interfering with the pathway 
involved with the phosphorylation of IκB.  Yin and colleagues (1998) further defined the 
inhibition mechanism by finding that SS specifically targets and irreversibly binds to IKK-β, but 
not IKK-α.  Therefore, SS inhibits the NF- κB pathway by blocking the ability of IKK to 
phosphorylate IκB, thereby inhibiting the release of NF-κB. 
 Link Between Inflammation and Insulin Resistance 
Insulin resistance plays a major role in the development of many metabolic health 
disorders including obesity, type 2 diabetes, hypertension, and cardiovascular disease (Kim et al., 
2001).  Insulin resistance is when tissue becomes less sensitive to insulin and fails to respond as 
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it normally would in the presence of insulin. Though the mechanisms that lead to insulin 
resistance are unknown, a link has been established between high levels of circulating free fatty 
acids and insulin resistance (Boden, 1997).  It is believed that elevated levels of plasma fatty 
acids interfere with the insulin signaling in muscle by inhibiting  phosphorylation of insulin 
receptor substrate (IRS) proteins, more specifically IRS-1 (Morino et al., 2006; Park et al., 2007).  
Hepatic insulin resistance is believed to be linked to fatty acids reducing the insulin-stimulated 
tyrosine phosphorylation of IRS-2 (Morino et al., 2006). 
Low-grade, or meta-inflammation, is a hallmark of type 2 diabetes and other metabolic 
disorders (Hotasmisligil, 2006).  High levels of circulating fatty acids can initiate the UPR, 
which leads to the activation of inflammatory pathways including the NF- κB pathway.  It thus 
stands to reason that inflammation may have a part in insulin resistance.  This link between low-
grade inflammation and insulin resistance has been confirmed (Xu et al., 2003).  Arkan and 
others (2005) performed a study where they fed a high fat/diabetes-inducing diet to a set of mice 
that lacked IKK-β enzymes in the hepatocytes and a set of mice lacking the enzymes in myeloid 
cells.  Mice that lacked IKK-β enzymes in the hepatocytes were protected from hepatic insulin 
resistance but still suffered from muscle and adipose insulin resistance.  Mice that lacked IKK- β 
in the myeloid cells were systemically protected from insulin resistance.  These results suggest 
that the NF-κB pathway is directly involved with fat-induced insulin resistance. 
Since salicylate inhibits inflammation through blocking IKK-β, salicylates have been 
evaluated as a potential therapeutic agent for type 2 diabetes.  There have been many reports that 
indicated that aspirin and SS prevent insulin resistance in obese or diabetic rats, mice, and 
humans (Kim et al., 2001; Yuan et al., 2001; Hundal et al., 2002; Park et al., 2007).  In addition 
to increased insulin sensitivity, Hundal and colleagues (2002) observed a 22% decrease in 
hepatic glucose production and a 24% decrease in fasting plasma glucose in human type 2 
diabetic patients after being treated for 2 weeks with 6.2 g/d of aspirin.  This could partially be 
caused by an increased uptake of glucose by peripheral tissues due to the increase of insulin 
sensitivity. 
 Use of Sodium Salicylate in Transition Dairy Cattle 
As stated previously, dairy cows undergo myriad metabolic changes around the time of 
parturition including an increase in circulating free fatty acids, low-grade inflammation, and 
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insulin resistance.  Some transition disorders and decreased milk production have been linked to 
these alterations, making the transition period an important economic period for the dairy farmer.  
By limiting the extent of inflammation and insulin resistance, there may be the potential to stop a 
metabolic transition disorder.   
Some research has been done in regard to using SS for its analgesic properties in calves 
during dehorning and castration, but little has been done to investigate the use of SS in the 
transition period.  Some work with other NSAIDS, such as ketoprofen and meloxicam (neither of 
which is in the salicylate family) have been done in transition dairy cows but the focus of these 
studies was on alleviation of pain associated with dystocia and the subsequent impact on milk 
production and reproduction (Richards et al., 2009; Newby et al., 2013).   
Flunixin meglumine, a member of the fenamate NSAID family, has been tested in 
transition cows.  Shwartz and others (2009) found that treating transition cows with flunixin for 
the first 3 d after calving had no effect on milk yield or plasma glucose levels, but did depress 
feed intake.   
In a previous study, SS was administered via water (1.95 g/L) to cows for 7 days after 
calving (Farney et al., 2013a, 2013b).  Treatment with SS had no effect on feed or water intake 
but decreased the pro-inflammatory cytokine TNF-α in plasma, indicating that SS did suppress 
inflammation.  Insulin sensitivity was increased in SS treated cows (measured via the RQUICKI 
equation) and mature (lactation 3+) cows experienced hypoglycemia on d 7.  This hypoglycemia 
was not accompanied by a decrease in mRNA expression of hepatic gluconeogenic genes, 
indicating that the increased insulin sensitivity could potentially be increasing the uptake of 
glucose by peripheral tissues.  Treated cows also experienced a ‘rebound’ increase in plasma 
NEFA and BHBA after they were removed from treatment.  Cows on treatment also experienced 
a greater degree of negative energy balance than the control cows.  Even though the SS cows 
seemed to be more metabolically distressed, they had greater milk production than the control 
cows.  In fact, 3+ lactation SS cows had a 21% higher 305-d milk yield than the control cows; 
however, the mechanism underlying this is unknown.  It is possible that SS may alter mammary 
gland function that in turn increased whole-lactation milk production.  This study has left many 
questions as to the exact mode of action of SS on glucose metabolism in ruminants as well as its 




Transition dairy cows undergo many metabolic changes similar to that of type 2 diabetes 
including increased plasma fatty acids, meta-inflammation, and insulin resistance.  Fatty acids 
can cause an inflammatory response, which has been linked to fat-induced insulin resistance.  
Many approaches have been taken in transition dairy cattle to reduce the level of circulating 
NEFA but another potential approach to decrease the amount of metabolic disorders is to 
mitigate inflammation.  One potential way to limit inflammation is to use NSAIDs, such as 
sodium salicylate.  There are still many unanswered questions as to the mode of action of SS on 
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Chapter 2 - Sodium Salicylate Decreases Glucose Turnover Rate in 
Periparturient Dairy Cows, Likely Through Enhanced Liver Insulin 
Sensitivity 
 Abstract 
Low-grade inflammation has been implicated as a contributor to metabolic disease during 
the transition to lactation.  In previous work, administration of sodium salicylate (SS) for 7 d led 
to hypoglycemia in mature dairy cows in early lactation.  The purpose of this study was to 
identify the mode of action underlying this response to SS.  Twenty mature (3+ parity) cows 
were assigned alternately at time of calving to either control (CON) or SS treatments.  CON 
treatment received a molasses carrier in drinking water while the SS received 2.5 g/L SS with the 
molasses carrier in drinking water for 7 d after parturition.  Blood samples were collected daily.  
A glucose turnover assay was performed on d 7, followed by liver, muscle, and adipose tissue 
biopsies.  Results were analyzed in the MIXED procedure of SAS with significance declared at P 
< 0.05.  There were no treatment effects on DMI (P = 0.98) or water intake (P = 0.61).  Tumor 
necrosis factor alpha (TNFa) mRNA expression was decreased by SS in adipose tissue (P = 0.09) 
but not in muscle (P = 0.97) or liver (P = 0.52).  Plasma haptoglobin was not altered by 
treatment (P = 0.34).  Though treatment did not alter plasma glucose or insulin concentrations, 
RQUICKI, a measure of insulin sensitivity, and plasma glucagon tended to be increased by SS 
(P = 0.08).  Insulin:glucagon was increased by SS (P = 0.01).  Cows on SS had a 25% decrease 
in glucose turnover rate (P = 0.05) compared to control cows.  There were no differences in 
mRNA expression of gluconeogenic genes in liver or of GLUT4 transporters in any of the 
tissues.  These results indicate that SS may increase insulin sensitivity in mature fresh cows.  
This increase in sensitivity of insulin could explain the lower glucose turnover rate because of 




Dairy cows undergo a variety of physiological changes during the transition period, 3 wk 
before to 3 wk after calving (Gummer 1995).  These changes include endocrine changes due to 
calving and metabolic changes due to a sudden increase in energy demand to synthesize milk, as 
well as being switched to a high-energy lactation diet (Drackley, 1999; Ingvartsen, 2006; 
Mulligan and Doherty, 2008).  Transition cows also exhibit symptoms similar to type-2 diabetes 
including mobilization of fat stores, elevated plasma non-esterified fatty acid (NEFA) levels 
(Contreras and Sordillo, 2011), and low-grade inflammation (Humblet et al., 2006) following 
parturition.    
Both high levels of circulating plasma NEFAs and chronic, low-grade inflammation have 
been linked to insulin resistance in humans and lab animals.  Insulin resistance, the decreased 
sensitivity of tissue to the presence of insulin, plays a major role in the development of many 
metabolic health disorders including obesity, type 2 diabetes, hypertension, and cardiovascular 
disease (Kim et al., 2001).   It is believed that elevated levels of plasma fatty acids interfere with 
the insulin signaling in muscle through inhibiting  phosphorylation of insulin receptor substrate 
(IRS) proteins, particularly IRS-1 (Morino et al., 2006; Park et al., 2007).  Hepatic insulin 
resistance is believed to be linked to fatty acids reducing the insulin-stimulated tyrosine 
phosphorylation of IRS-2 in humans (Morino et al., 2006).   
Inflammatory pathways including the NF-κB pathway are also stimulated during the 
transition period and can impair many metabolic functions (Zhang and Kaufman, 2008).  There 
are a number of stimuli for this activation including endoplasmic reticulum (ER) stress, high 
levels of circulating lipids, and infection (Hotamisligil, 2010).  Arkan and others (2005) fed a 
high fat/diabetes-inducing diet to a set of mice that lacked IKK-β enzymes in the myeloid cells.  
The role of IKK-β is to activate NF-κB, which will then stimulate an inflammatory response 
(Baker et al., 2011).  Mice that lacked IKK- β in the myeloid cells were systemically protected 
from insulin resistance.  These results suggest that the NF-κB pathway is directly involved with 
fat-induced insulin resistance. 
In dairy cows, reducing the effectiveness of insulin seems to facilitate the funneling of 
the available glucose to the mammary gland to be used as energy for milk synthesis (Giesy et al., 
2012).  This diversion of almost 85% of the circulating glucose to the mammary gland 
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contributes to a severe negative energy balance and the cow is forced to mobilize more adipose 
tissue to make up the difference, which can lead to a variety of metabolic disorders (Sordillo et 
al., 2009).   
One potential method to increase systemic insulin sensitivity is to mitigate inflammation.  
The supplementation of sodium salicylate (SS), a non-steroidal anti-inflammatory drug 
(NSAID), may decrease insulin resistance and the disruptive effects that inflammation may have 
on other metabolic processes.  Sodium salicylate, though a weak cyclooxygenase (COX) 
inhibitor, has been shown to inhibit the NF-κB pathway by impairing the ability of IKK- β to 
activate NF-κB (Yin et al., 1998).  In a previous study (Farney et al., 2013a; Farney et al., 
2013b), SS was given to cows for 7 d postpartum.  Mature cows (3+ parity), but not younger 
cows, exhibited hypoglycemia on d 7 through an unknown mechanism.  The purpose of this 
study was to investigate the mechanism behind this hypoglycemia in the mature cows and to 
determine the extent to which SS alters glucose kinetics and insulin sensitivity. 
 Materials and Methods 
 Animals, Treatments, and Care 
All procedures were approved by the Kansas State University Institutional Animal Care 
and Use Committee (protocol # 3182).  Cows were housed in the Kansas State University Dairy 
Unit Tie-Stall Facility for the duration of the trial.  Twenty mature cows (3
rd
 parity) were 
enrolled 4 to 36 h after parturition and were alternately assigned to 1 of 2 treatments for 7 d.  
Cows that experienced dystocia (calving difficulty 3+) or had multiple births were not enrolled.  
The first treatment was 2.5 g/L sodium salicylate (SS) with a molasses carrier (0.15 g/L) that was 
delivered to the cow via the drinking water supply.  The second treatment was a control (CON) 
treatment, which supplied the cow with 0.15 g/L of the carrier molasses only in drinking water.  
After the 7-d treatment, cows were switched to normal water and removed from the tie-stall barn 
to rejoin the herd within 72 h. 
Upon calving, all cows were given 1 bottle of Milk Fever CP (Aspen Veterinary 
Resources Ltd., Liberty, MO) subcutaneously and 454 g of the electrolyte mixture Fresh Cow 
YMCP (TechMix Inc., Stewart, MN) orally.  One tube of CMPK Gel Plus (Vet Plus Inc., 
Menomonie, WI) was given orally once daily for the first 3 d postpartum.  Urine ketones (ReliOn 
Ketone Strips, Wal-Mart Inc., Bentonville, AZ) and temperatures were monitored daily.  Cows 
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with high urinary ketone concentrations (≥80 mg/dL) for 1 d or moderate ketones (40-80 mg/dL) 
for 2 consecutive days were treated per farm protocol.  Cows exhibiting a temperature above 
103.0°F were treated with antibiotics.  Cows diagnosed with a displaced abomasum before d 7 
were removed from study, though all data collected before removal was used for analysis. 
Cows were milked 3 times daily at 8-h intervals.  Cows were fed ad libitum twice daily at 
630 h and 1600 h.  Feed and water intake were recorded daily.  Diet DM was 50.1%; it contained 
17.43% CP, 38% NDF, and 23.6% ADF on a DM basis.  Body weight (BW) and body condition 
scores (BCS) were recorded on d 1 and d 9. 
  Procedures and Sample Collections 
Blood was collected into EDTA (6 mL) and sodium fluoride (6 mL) tubes (Vacutainer; 
Becton, Dickinson and Co., Franklin Lakes, NJ) from coccygeal vessels on d 1-7.  The samples 
were then immediately centrifuged at 2,000 x g for 15 min and plasma was stored at -20°C until 
analyzed.  Milk samples were collected 3 times daily on d 4-7. 
On d 5, cows were fitted with a guidewire-style jugular catheter (Mila International Inc., 
Erlanger, KY).  Under local anesthesia, a 14-gauge needle was used to access the jugular vein.  
A 45-cm long guidewire was threaded through the needle.  The catheter (20 cm) was then strung 
onto the wire and was guided into the jugular vein.  The catheter was flushed twice daily with 5 
mL of a sterile solution of 3.5% sodium citrate to prevent clotting. 
On d 7, a glucose turnover assay was performed.  Beginning with the morning feeding, 
cows were fed equal amounts of the diet every two hours to meet steady-state requirements.  At 
1230 h, 1 g of U-
13
C-glucose (99 atom %, Sigma Chemical Co., St. Louis, MO) dissolved in 50 
mL saline was infused into the jugular vein via catheter in a bolus dose: syringes were weighed 
immediately before and after infusion to determine the exact amount administered.  Jugular 
blood samples were collected 10 min before infusion and at 10, 20, 30, 40, 50, 60, 90, and 120 
min post-infusion.   
Immediately after the completion of the glucose turnover assay, liver, muscle, and 
adipose tissue biopsies were performed.  Liver samples were taken as described previously 
(Morey et al., 2011)  Approximately 200 mg of liver tissue (10 biopsies) were collected, snap-
frozen in liquid nitrogen, and stored at -80°C until analyzed.   
For the adipose tissue biopsies, the area between the tailhead and pin bone was used.  The 
area was clipped, scrubbed, and a local anesthesia was applied (lidocaine hydrochloride; Agri 
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Laboratories Ltd., St. Joseph, MO).  A 3 cm-long incision was made with a #22 blade (Feather 
Sterile Surgical Blade; GF Health Products Inc., Atlanta, GA).  Subcutaneous adipose tissue was 
collected from the incision site with sterile forceps and surgical scissors.  Approximately 5 g of 
tissue was collected, snap-frozen in liquid nitrogen, and stored at -80°C until analyzed.  After 
tissue collection, the incision site was stapled closed. 
Muscle tissue biopsies were collected at the first lumbar vertebra.  The area was 
aseptically prepared and a local anesthesia was given (lidocaine hydrochloride; Agri 
Laboratories Ltd.).  A 12-gauge needle was used to initially breech the skin to allow the biopsy 
needle access to the muscle tissue.  A 14-gauge, 9 cm-long biopsy needle (SABD-1409-15-T; US 
Biopsy, Franklin, IN) was inserted through the initial hole, perpendicular to the Longissimus 
dorsi lumborum muscle fibers.  Approximately 300 mg of muscle tissue was extracted, snap-
frozen in liquid nitrogen, and stored at -80°C until analyzed. 
 Plasma Analysis 
Plasma samples were analyzed for glucose (kit #439-90901; Wako Chemicals USA Inc., 
Richmond, VA), insulin (#10-1201-01; Mercodia AB, Uppsala, Sweden), BHBA (#H7587-58; 
Pointe Scientific Inc., Canton, MI), non-esterified fatty acids (NEFA-HR; Wako Chemicals USA 
Inc.), glucagon (# GL-32K, Millpore, Billerica MA), TNFa (Farney et al, 2011), lactate (#L7596-
50; Pointe Scientific Inc.), and haptoglobin (Cooke and Arthington, 2013). 
Glucose turnover test samples were analyzed for total glucose concentration to ensure 
steady-state requirements were met and then were analyzed for U-
13
C-glucose to determine the 
enrichment of plasma glucose (Metabolic Solutions, Inc., Nashua, NH).  Glucose was extracted 
and converted to aldonitrile pentaacetate derivative (Tserng and Kalhan, 1983), and negative 
chemical ionization GC/MS (Hewlett-Packard 5890) was used to analyze derivatized samples. 
The isotopic composition of the glucose was determined by monitoring unlabeled (M+0: m/z = 
328) versus U-13C-labeled (M+6: m/z = 334) glucose derivatives.  Enrichment of plasma 
glucose for each animal was fitted to an exponential decay curve using the following equation: 
Et = E0 × e-kt, where t = time relative to infusion (min), Et = enrichment of plasma glucose (U-
13
C-glucose: unlabeled glucose ratio) at time t, E0 = enrichment at time t = 0, and k = rate 
constant (min-1). After using the best-fit equations to determine k and E0, the total glucose pool 
was calculated by this equation: G = M ÷ E0, where G = total glucose pool (g) and M = mass of 
tracer infused (g). Plasma glucose turnover rate (GTR, g/min) was calculated by the equation 
23 
 
GTR = G × k. Samples collected 10 min prior to infusion of U-
13
C-glucose were also analyzed to 
verify the lack of natural occurrence of the M+6 isotopomer. 
The revised quantitative insulin sensitivity check index (RQUICKI) was used as an 
indirect measure of insulin sensitivity.  The following equation was employed: RQUICKI = 
1/[log (Gb) + log (Ib) + log (FFAb)] (Perseghin et al., 2001).  This equation has been validated 
for the use in dairy cattle (Holtenius and Holtenius, 2007). 
 Tissue Sample Analysis 
Total RNA was isolated from all tissue types (RNeasy Lipid Tissue Mini Kit; Qiagen 
Inc., Valencia, CA) and RNA was quantified via spectroscopy (NanoDrop Technologies Inc., 
Wilmington, DE).  All adipose samples and 5 randomly selected muscle and liver samples were 
analyzed for RNA integrity (Agilent 2100 Bioanalyzer; Agilent Technologies, Santa Clara, CA).  
Complementary DNA was synthesized from RNA (High Capacity cDNA Reverse Transcription 
kit; Applied Biosystems, Foster City, CA).  The synthesized cDNA was then used in quantitative 
real-time PCR in duplicate using SYBR green fluorescent detection (7500 Fast Real-Time PCR 
system, Applied Biosystems).  All genes and primes are listed in Table 2.1.  All sample values 
were normalized against the geometric mean of RPS9, RPS15, and β-actin values and the results 
are expressed as fold changes of threshold cycle (2
-ΔCt
) value relative to control. 
 Statistical Analysis 
Measurements are expressed as means ± S. E.  Statistical analysis was carried out in the 
Mixed Procedure of SAS (version 9.3 SAS institute Inc., Cary, NC).  Results were modeled with 
the fixed effects of treatment, day, and treatment × day interaction.  Repeated measures within 
cow were modeled with an autoregressive (AR[1]) covariance structure.  Day 1 plasma samples 
were taken before cows were put on treatment, so d1 values were used as a covariate just for the 
analysis of plasma metabolites.  Several variables (all mRNA results from tissue except adipose 
GLUT4 and HSD11B1 and muscle PGC1a) were natural log-transformed for statistical analysis 
to achieve normal residual distributions, and reported means were back-transformed.  Tendencies 
were declared at P < 0.1 and significance declared at P < 0.05. 
 Results 
 Water and Dry Matter Intake 
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There was no difference between treatments in water (P = 0.61) intake, indicating that 
there was little to no palatability issues with the SS treatment (Fig. 2.1).  There was also no 
difference in DMI (P = 0.98; Figure 2.1). 
 BW and BCS 
Day 1 BCS for CON and SS cows were 3.6 ± 0.17 and 3.47 ± 0.16 respectively (trt x day 
P = 0.58).  Day 9 BCS for CON cows was 3.29 ± 0.16 and 3.29 ± 0.17 for SS cows (trt P = 
0.76).  There was no difference in BW between CON and SS treatments on d 1 (776 ± 21 kg vs. 
777 ± 22 kg; P = 0.97) or d 9 (739 ± 21 kg vs. 735 ± 22 kg; P = 0.89).  On average across 
treatments, cows lost 0.25 ± 0.11 BCS units and 40 ± 15 kg of BW. 
 Blood Metabolites and Glucose Turnover Test 
Plasma NEFA, BHBA, and lactate concentrations were not affected by treatment (all P > 
0.32; Fig. 2.2). Neither haptoglobin, an acute phase protein, nor TNFa, a proinflammatory 
cytokine, were altered by treatment (P > 0.34; Fig. 2.2). 
Glucose and insulin levels were similar across treatments (P = 0.25 and P = 0.13 
respectively; Fig. 2.3).  However, RQUICKI, a measure of insulin sensitivity which takes into 
account glucose, insulin, and NEFA concentrations, tended to be greater (more sensitive) in SS 
treated cows (P = 0.09; Fig. 2.3).  Glucagon, a stimulator of gluconeogenesis, tended to be 
elevated by SS treatment (P = 0.08; Fig. 2.4).  The glucagon:insulin ratio was greater in CON 
cows (P = 0.01; Fig 2.4).  The glucose turnover rate, an indicator of gluconeogenesis, was 25% 
less in SS treated cows than CON cows (P = 0.055; Fig. 2.4). 
 mRNA Abundance 
Inflammatory cytokine tumor necrosis factor alpha (TNFa) mRNA abundance was 
decreased by SS in adipose tissue (P = 0.09) but not in muscle (P = 0.97) or liver (P = 0.52; 
Table 2.2).  Treatment had no effect on hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), 
which converts cortisone to cortisol, in any of the 3 tissues (P > 0.67).  Insulin-dependent 
glucose transporter GLUT4 mRNA expression was also unaltered by SS treatment in these 
tissues (P > 0.63).  Liver gluconeogenic genes glucose-6-phosphatase (G6PC), pyruvate 
carboxylase (PC) and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha 




Treatment with SS did not significantly alter the inflammatory status of the cows between 
treatments based on the lack of change in plasma haptoglobin and TNFa levels, as well as muscle 
and liver TNFa mRNA.  Contrary to our previous study, there were only numeric differences in 
plasma glucose levels and no hypoglycemia (Farney et al., 2013a).     
High levels of circulating fatty acids can induce insulin resistance (Boden, 1997).  It is 
believed that high levels of fatty acids cause a build-up of intracellular fatty acid metabolites 
such as ceramides which activate the serine/threonine kinase cascade, leading to the serine 
phosphorylation, and subsequent inhibition, of insulin receptor substrates (IRS-1 and IRS-2; 
Shulman, 2000).  The inhibition of IRS-1 and IRS-2 leads to a decrease in insulin dependent 
glucose transport, specifically GLUT4, and thus insulin resistance.  Increasing insulin sensitivity 
would reduce the inhibition of IRS-1 and IRS-2 and subsequently increase insulin dependent 
glucose transporters.  Though RQUICKI did identify that SS treated cows had increased insulin 
sensitivity, there was no increase in GLUT4 mRNA in SS treated cows, although there may be 
differences at the protein level between treatments.  Farney and colleagues (2013a) also saw an 
increase in RQUICKI on d 7 in SS treated cows.   
One mechanism of SS is to impair the ability of IKK- β to activate the NF-κB 
inflammatory pathway (Yin et al., 1998).  Arkan and colleagues (2005) also linked IKK- β to 
insulin resistance.  Therefore, SS, which hinders IKK- β activity, may also increase insulin 
sensitivity.  This has been confirmed by a variety of reports in obese or diabetic rats, mice, and 
humans (Kim et al., 2001; Yuan et al., 2001; Hundal et al., 2002; Park et al., 2007).  In contrast, 
Farney and colleagues (2013a) did not see a difference in liver nuclear NF-κB abundance 
following SS treatment in cows, suggesting that there was not extensive impairment of IKK- β 
function.  While the impairment of IKK- β may have had some role in the increased insulin 
sensitivity, there may be other mechanistic actions of SS that could contribute to the increased 
sensitivity of insulin.   
Insulin inhibits gluconeogenesis; an increased response to insulin could explain why the 
glucose turnover rate decreased 25%.  Glucose turnover rate is a good measure of 
gluconeogenesis because net portal appearance of glucose is minimal (Reynolds et al., 1988).  
Insulin has been shown to directly inhibit the pro-gluconeogenic genes PGC1a and G6P (Barthel 
and Schmoll 2003; Pugiserver et al., 2003). The fact that there was no difference in liver 
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gluconeogenic mRNA abundance indicates that the alteration in gluconeogenesis may occur 
post-transcriptionally.   
Glucagon, a stimulator of gluconeogenesis, was increased in SS treated cows.  Glucagon 
and insulin act inversely in regulating glucose metabolism; insulin suppresses while glucagon 
stimulates gluconeogenesis (Pilkis et al., 1988; Pilkis and Granner, 1992).  The insulin:glucagon 
ratio was lower in SS treated cows, which may reflect a scenario where more glucagon was 
provided to override the more sensitized response to insulin.  Even with higher glucagon 
concentrations and increased insulin sensitivity, gluconeogenic mRNA expression was not 
changed.  Plasma glucose and insulin levels were similar in both treatments indicating that SS 
treated cows needed more glucagon to achieve the same level of glucose as CON cows, probably 
due to the increased sensitivity of insulin to hinder gluconeogenesis.  In fact, Mamedova and 
colleagues (2013) found evidence that inflammatory signaling through toll-like receptor 4 
(TLR4) promoted gluconeogenic gene expression in human hepatocellular carcinoma cells.  If 
inflammation increases gluconeogenesis, it is probable that treatment with an anti-inflammatory 
agent would suppress gluconeogenesis.  Although glucose and insulin levels in the current study 
were numerically lower in SS treated cows, there was no evidence of hypoglycemia, unlike a 
similar study (Farney et al., 2013a).  One possible explanation for this discrepancy is the lack of 
power due to low animal numbers in the current study; 20 cows were used whereas Farney and 
colleagues (2013a) had 78 cows. 
One mechanism of action of SS that could account for the post-transcriptional alteration 
in glucose metabolism is the ability of SS to activate AMP-activated protein kinase (AMPK; 
Hawley et al., 2012).  It should be noted that the SS dose used by Hawley and colleagues (2012) 
was much higher than normally used in vitro (3+ mM v. 50-200 μM) in order to see a large, 
significant change. When activated, AMPK turns on catabolic (ATP generating) processes, such 
as fatty acid oxidation and glucose uptake, and turns off anabolic (ATP consuming) processes 
such as gluconeogenesis (Hardie, 2008).  In the short-term, AMPK alters protein function, such 
as activating already existing GLUT4 transporters and deactivating gluconeogenic enzymes, and 
only alters gene expression in the long term (Hardie, 2008).  The activation of already existing 
GLUT4 transporters could account for the numerically lower glucose concentrations in SS 
treated cows with no difference in GLUT4 mRNA expression.  Rainsford (2004) suggested that 
SS treatment increased the conversion of pyruvate to lactate since the creation of glucose from 
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pyruvate was inhibited due to AMPK activation; however the current study did not detect any 
treatment difference in lactate levels.  Activation of AMPK has also been linked to a decrease in 
insulin resistance, although the exact mechanism for this is unknown (Ruderman et al., 2003).   
 Conclusion 
Treatment with the NSAID sodium salicylate increased insulin sensitivity in mature 
transition cows.  Although there were no differences in plasma glucose or insulin levels, glucose 
turnover rate was decreased in SS treated cows.  There was no detectible difference between 
treatments in mRNA expression of gluconeogenic genes or the insulin dependent glucose 
transporter GLUT4, indicating that the alteration SS had on glucose metabolism likely occurred 
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 Forward primer (5'-3') 
Reverse primer (5' -3') 






β-actin  NM_173979.3  
ACGACATGGAGAAGATCTGG 
ATCTGGGTCATCTTCTCACG 






PC  NM_177946.4  
CTTCAAGGACTTCACTGCCACC 
GCCAAGGCTTTGATGTGCA 
HSD11B1  NM_001123032.1 
AGCATTGTGGTCGTCTCCTC 
TACGCAGCAACAAGTGGACA 
GLUT4  NM_174604.1 
TAGCCATCGTCACTGGCATC 
AGGAGGAGTGGCCATAAGGT 




RPS9, ribosomal protein subunit 9; RPS15, ribosomal protein subunit 15; TNFa, tumor necrosis 
factor alpha; PGC1a, peroxisome proliferator-activated receptor-gamma coactivator-1 alpha; PC, 
pyruvate carboxylase; HSD11B1, 11β-hydroxysteroid dehydrogenase type 1; GLUT4, glucose 
transporter type 4; G6PC, glucose-6-phosphatase.  
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There were no differences in DM or water intake between treatments.  It is interesting to note 
that cows on SS treatment had a numerically lower water intake (B) on days 1 through 3.  This is 
probably due to palatability issues.  Even though molasses was used to mask the bitter taste of 
SS, it is possible that it took the cows a few days to acclimate to the taste.
33 
 
Figure 2.2 Plasma metabolites  
 
 
There were no differences in the plasma energy balance markers NEFA and BHBA between treatments (A and B).  A suppression of 
hepatic gluconeogenesis could lead to an increase in lactate, however there were no differences in plasma lactate concentration 
between SS and CON treatments (C).  Although SS is an anti-inflammatory agent, the plasma concentrations of the acute phase 
protein haptoglobin (D) and the inflammatory cytokine TNFa (E) were not altered by the treatment of SS. 
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Figure 2.3 Plasma glucose, insulin, and insulin sensitivity  
 
 
There was no treatment effect on plasma glucose and insulin concentrations (A and B).  Insulin 
sensitivity was measured using the RQUICKI equation, which takes into account plasma insulin, 
glucose, and NEFA levels.  Cows treated with SS tended to have a higher RQUICKI (more 
insulin sensitive) than the CON cows (C).  
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Figure 2.4 Glucagon and glucose turnover rate 
 
 
Glucagon, a hormone that stimulates gluconeogenesis, tended to be higher in SS cows (A).  The 
insulin:glucagon ratio was lower in SS treated cows, indicating that SS cows had more glucagon 
per unit of insulin circulating in plasma (B).  Glucose turnover rate (GTR), a measure of 












Muscle TNFa 0.57 ± 0.38 0.41 
 
HSD11B1 0.28 ± 0.26 0.30 
 
GLUT4 0.82 ± 0.28 0.65 
 
PGC1a 0.28 ± 0.49 0.48 
    Adipose TNFa 0.24 ± 0.35 0.09 
 
HSD11B1 1.20 ± 0.55 0.79 
 
GLUT4 1.52 ± 0.28 0.20 
    Liver TNFa 0.42 ± 0.57 0.43 
 
HSD11B1 1.10 ± 1.92 0.96 
 
GLUT4 0.89 ± 0.91 0.93 
 
G6PC 1.42 ± 1.68 0.83 
 
PC 2.32 ± 2.50 0.62 
  PGC1a 0.20 ± 0.47 0.14 
1
Fold differences of SS treatment when CON=1. 
 
There was a tendency in adipose, but not liver or muscle tissue, for mRNA expression of the 
inflammatory cytokine TNFa to be lowered by SS treatment.  Treatment with SS did not alter 
expression of gluconeogenic genes in the liver or glucose transporter GLUT4 in any tissue.  
There were not treatment differences in the expression of HSD11B1, which is involved in 




Chapter 3 - Sodium Salicylate Does Not Alleviate Palmitate-Induced 
Endoplasmic Reticulum Stress in Immortalized Bovine Mammary 
Epithelial Cells 
 Abstract 
Palmitate (PALM) has been shown to induce endoplasmic reticulum (ER) and oxidative 
stress in some cell types, whereas sodium salicylate (SS) and unsaturated fatty acids have been 
shown to mitigate these stresses.  Therefore, we hypothesized that SS would counteract the 
effects of PALM in immortalized bovine mammary epithelial (MAC-T) cells.  In the first 
experiment, MAC-T cells were treated with SS (50 µM), PALM (250 µM) or oleate (OLEIC; 
500 µM), alone or in combination.  To determine if PALM effects were due to ceramide (CER) 
synthesis, a second experiment was conducted where MAC-T cells were treated with PALM 
(250 µM), myriocin (MY; 1 µM; CER synthesis inhibitor), or both in the same basal media.  In a 
third experiment, cells were treated with SS and PALM alone and in combination and were 
harvested at 3, 6, 12 and 24 h of incubation.  An extracellular ROS assay was performed in 
experiment four where cells were treated as in experiment three but harvested at 180 min of 
incubation.  The fourth experiment was replicated using human hepatocellular carcinoma 
(HepG2) cells.  Results from replicate wells (6 to 12/treatment) were analyzed by ANOVA and 
treatment effects were declared significant at P < 0.05.  PALM increased mRNA abundance of 
the ER stress response targets XBP-1 (4-fold, P < 0.01), ATF3 (46-fold, P < 0.001), and CHOP 
(34-fold, P < 0.001), but neither SS nor OLEIC affected these transcripts (P > 0.10).  The XBP-1 
transcript is also spliced during the ER stress-response.  PALM increased the proportion of XBP-
1 that was spliced (3.8 vs. 13.6 ± 2.2%, P < 0.001); this effect was not counteracted by SS or 
OLEIC.  MY treatment ablated the XBP-1 mRNA and XBP-1 splicing responses to PALM (P < 
0.05) but further increased CHOP and ATF3 mRNA abundance (P < 0.001).  PALM had no 
effect on TBARS (a measure of oxidative products), but decreased extracellular ROS levels (P < 
0.001).    These results demonstrate that PALM induced ER stress in MAC-T cells, in part 




Chronic, low-grade inflammation is a hallmark of metabolic disorders, such as obesity 
and type 2 diabetes.  This meta-inflammation has been linked to metabolic dysfunctions such as 
insulin resistance (Kim et al., 2001; Ozcan et al., 2004; Zhang and Kaufman, 2008; Hotamisligil, 
2010; Back and Kaufman, 2012).  Inflammation can be induced by a variety of pathways 
including the unfolded protein response (UPR), which occurs when the endoplasmic reticulum 
(ER) is stressed.   
Endoplasmic reticulum stress occurs when the demand for protein folding cannot be met 
by the ER, causing an increase in the amount of misfolded and unfolded proteins that the ER 
releases into the host body.  The purpose of the UPR is to protect the host by returning the 
stressed ER to homeostasis by altering cell function to make up for the protein folding deficit.  In 
the event that this alteration does not resolve the protein shortage, the UPR initiates apoptosis to 
protect the host from the potential release of mass quantities of malfunctioning proteins, which 
can have toxic effects (Tabas and Ron, 2011; Moore and Hollien, 2012).  A variety of stimuli can 
induce ER stress such as high levels of circulating free fatty acids (FFA), glucose, and 
proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α; Zhang and Kaufman, 
2008).   
The UPR cascade has three starting points, which consist of inositol-requiring 1α (IRE1), 
double-stranded RNA-dependent protein kinase (PKR)- like ER kinase (PERK), and activating 
transcription factor 6 (ATF6; Zhang and Kaufman, 2008).  During normal ER function, these 
sensors are inactive due to the attachment of immunoglobulin-heavy-chain-binding protein (BiP 
or GRP78).  BiP has a high affinity for misfolded and unfolded proteins, so when there is a large 
build-up of these, BiP will detach from the three arms and attach to the misfolded proteins, thus 
activating the UPR (Kaufman, 2002; Hotamisligil, 2010). 
 Once BiP is detached, PERK is phosphorylated, allowing it to phosphorylate eukaryotic 
initiation factor 2α (eIF2α).  This phosphorylation inhibits the synthesis of new proteins in an 
attempt to slow down the buildup of misfolded and unfolded proteins (Zhang and Kaufman, 
2008).  The phosphorylation of eIF2α also allows for the translation of activating transcription 
factor 4 (ATF4), which then enters the nucleus of the cells and upregulates target genes involved 
with amino acid biosynthesis, oxidative stress response and apoptosis (Hotamisligil, 2010). 
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When the IRE1 branch is activated, IRE1 auto-phosphorylates.  IRE1 then splices X-box-
binding protein-1 (XBP-1) into its active form, referred to here as XBP-1s.  XBP-1s is a key 
factor for transcription during ER stress.  XBP-1s travels to the nucleus and induces transcription 
of genes that code for ER chaperones and enzymes involved with protein folding, maturation, 
and export (Zhang and Kaufman, 2008).  ATF6 follows a similar pathway to IRE1 when 
activated.  ATF6 migrates to the Golgi apparatus and is cleaved by site-1 protease (S1P) and 
S2P.  The remaining fragment of ATF6 then goes to the nucleus and follows the same pathway 
as XBP-1s (Hotamisligil, 2010).  In the event where the UPR is unable to revert the ER back to 
homeostasis through the alteration of cell transcription, the UPR will then initiate apoptosis, 
which is mainly mediated by CCAAT/enhancer-binding protein homologous protein (CHOP).   
The UPR is linked with inflammatory pathways such as the nuclear factor-κB (NF-κB) 
and JUN N-terminal kinase (JNK).  The branches of UPR can directly initiate an inflammatory 
response or act indirectly through accumulation of reactive oxygen species (ROS).  The ER 
stores a large amount of calcium, but when there is an accumulation of misfolded and unfolded 
proteins, calcium begins to leak out of the ER and is taken up into the mitochondria.  In the 
mitochondria, calcium disrupts normal functions by depolarizing the mitochondrial membrane 
and disrupting the electron transport chain (Zhang and Kaufman, 2008).  This leads to an 
increase of ROS production, and a subsequent onset of oxidative stress.  High levels of ROS 
initiate NF-κB and JNK pathways since ROS are important mediators in these pathways, which 
leads to an upregulation of specific genes involved with cell proliferation and the release of 
cytokines to activate an immune response (Baker et al., 2011).   
Sodium salicylate (SS) is a member of the salicylate group of non-steroidal anti-
inflammatory drugs (NSAIDs), of which aspirin is also a member.  After consumption, SS is 
quickly converted to salicylic acid (Amann and Peskar, 2002).  Though a weak cyclooxygenase 
(COX) inhibitor (Smith et al., 1975; Kopp and Ghosh, 1994), SS has been shown to inhibit NF-
κB activation (Kopp and Ghosh, 1994, Yin et al., 1998) and uncouple oxidative phosphorylation, 
leading to an increase of extracellular adenosine release (Cronstein et al., 1999). 
Evidence also suggests that NSAIDs may exhibit their anti-inflammatory effects by 
increasing the UPR.  Tsutsumi and colleagues (2004) reported that CHOP, the apoptotic 
component of UPR, was involved in NSAID-induced apoptosis they observed in pig gastric 
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mucosal cells.  They also noted that other UPR components such as XBP-1, ATF-6, and ATF-4 
were upregulated in the presence of SS. 
In this series of experiments, our aim was to assess the ability of SS to inhibit the UPR 
and inflammatory response, which was induced by the presence of the fatty acid palmitate 
(C16:0).  We also assessed the ability of SS to decrease ROS production in ER stressed cells. 
 Materials and Methods 
Immortalized bovine mammary epithelial (MAC-T) cells (Huynh et al., 1991) were 
graciously donated by Dr. Wendi Cohick from Rutgers University.  Dulbecco’s modified Eagle’s 
medium (DMEM 1x; ref # 11965-092, Life Technologies, Grand Island, NY) containing 10% 
fetal bovine serum (FBS; cat #: S01520, Biowest, Kansas City, MO), 1% penicillin streptomycin 
(# 15070, Life Technologies), 1% insulin (# I9278; Sigma Aldrich, St. Louis, MO), and 2% 
bovine serum albumin (fatty acid free BSA; # A8806-5G, Sigma Aldrich) was used in all 
experiments.  Cells were cultured at 37°C with 5% atmospheric CO2.  Before treatments, all cells 
were cultured for 24 h to reach at least 80% confluence.  Cells were then washed with phosphate 
buffered saline (PBS) before fresh medium and treatment were added.  After the designated 
incubation time, the medium was removed, and cells washed with cold PBS.  Cells were frozen 
with Trizol, mixed with beta mercaptoethanol, and stored at -20°C until RNA was harvested 
unless otherwise stated. 
 Treatments 
In the first experiment, cells were treated with sodium salicylate (SS; 50 μM), palmitate 
(PALM; 250 μM), or oleate (OLEIC; 500 μM), both alone and in combination and incubated for 
24 h.  For the second experiment, cells were treated with PALM (250 μM) or myriocin (MY; 1 
μM) or both and incubated for 24 h.  Myriocin is a known ceramide (CER) synthesis inhibitor 
(Chavez and Summers, 2012).  
A third experiment was performed to monitor treatment effects over time.  Cells were 
treated with SS (50 μM) or PALM (250 μM) or both.  Cells were harvested after 3, 6, 12, and 24 
hours of incubation.  In a fourth study, cells were treated as in the third experiment with or 
without BSA, and medium was collected at 15, 30, 45, 60, 120, and 180 minutes of incubation. 
 Measurement of Oxidative Stress 
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Oxidative stress was quantified in two ways.  The first method employed was 
measurement of thiobarbituric acid reactive substances (T-BARS Kit #10009055: Cayman 
Chemical Co., Ann Arbor, MI).  Cells from experiment one were used for this analysis.  Briefly, 
cells in Trizol were thawed and put into a 5 mL vial with 100 μL SDS solution and 4 mL of color 
reagent provided in the kit.  The vials were then placed in boiling water for 1 h, incubated on ice 
for 10 min, centrifuged for 10 min at 1,600 x g at 4°C, then 150 μL from each vial was added to 
a 96-well plate and absorbance was read at 540 nm. 
The medium from experiment four was used to measure extracellular oxidative stress 
with the acridan lumingen PS-3 assay (Uy et al., 2011).  Briefly, the working reagent for this 
assay, ALPS-3 substrate, was created by mixing reagents A and B from western blotting kits in a 
40:1 ratio (Amersham ECL Plus kit, GE Healthcare).  Medium (50 μL) was pipetted in triplicate 
into a 96-well chemiluminescence plate.  50 μL of PBS and the ALPS-3 substrate were added to 
the medium and the plate was incubated in darkness for 5 min before analysis of 
chemiluminescence (Wallac Victor
2
 1420 Multilabel Counter).  
To validate results from the acridan lumigen PS-3 assay, we treated hepatocellular 
carcinoma (HepG2; HB-8065 purchased from ATCC, Manassas, VA) cells with SS (50 μM) or 
palmitate (250 μM) or both, either with or without BSA, and incubated the cells for 24 h.  The 
medium was harvested and used in the acridan lumigen PS-3 assay. 
 Histochemical Assay  
Hematoxylin and eosin (H&E) staining was performed at the 24 h time point of 
experiment three.  Treated cells were washed with PBS, fixed with methanol for 10 min, then 
washed again with PBS.  Fixed cells were incubated for 3 min in hematoxylin solution (35.2 g/L 
aluminum sulfate, 0.4 g/L sodium iodate). After 3 washes for 5 min each in PBS, the sections 
were allowed to air dry before glycerol was added. The image was visualized with a Nikon TMS 
microscope (Sheerin Scientific Co. Inc., Shawnee, KS) and images were taken using a digital 
camera (Nikon E995, Japan). 
Transcript Abundance 
For all experiments, RNA was extracted from cells in 1 mL ice-cold Trizol reagent 
(Qiagen RNeasy Lipid Tissue Mini Kit, Valencia, CA) according to manufacturer specifications 
and quality was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
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CA).  Total RNA amount was used to synthesize cDNA using a High-Capacity cDNA reverse 
transcription Kit (Applied Biosystems, CA).   
Quantitative real-time PCR was performed in triplicate with 5% of the cDNA product in 
the presence of 200 nmol/L gene-specific forward and reverse primers using SYBR green 
fluorescent detection (ABI 7500 Fast, Applied Biosystems). Relative abundance of mRNA was 
quantified using the 2
-∆Ct
 method with an ABI Prism 7000 Sequence detector (Applied 
Biosystems, CA) instrument. All sample values were normalized against the geometric mean of 
RPS9 and RPS15 values.  Results were expressed as fold changes relative to normalization 
transripts. 
 Statistical Analysis 
Results from replicate wells (6 to 12/treatment) were analyzed by ANOVA (JMP 8.0, 
SAS Institute) to assess fixed effects of each treatment factor and interactions.  Individual 
treatment contrasts were evaluated by Tukey’s HSD.  Several variables (XBP-1, XBP-1s, ATF3, 
CHOP, TBARS, TNFa, and IL-1B) were natural log-transformed for statistical analysis to 
achieve normal residual distributions, and reported means were back-transformed.  Treatment 
effects were declared at P < 0.05 and tendencies at P < 0.10. 
 Results and Discussion 
 Experiment 1 
In a 24-h period, PALM, a known ER stress inducer (Karaskov et al., 2006; Jeffrey et al., 
2008), increased mRNA expression of total (active and inactive) XBP-1 (P < 0.01), while neither 
OLEIC, which has been shown to mitigate the ER stress effect of PALM in muscle cells (Peng et 
al., 2011), or SS were able to counteract this effect (P > 0.46; Fig. 3.1).  Treatment with PALM 
also increased XBP-1s while SS and OLEIC again did not alter the effect of PALM (Fig. 3.1).  
The most prominent mediator of apoptosis, CHOP, also increased with PALM treatment (P < 
0.01).  Neither SS nor OLEIC were able to counteract the pro-apoptotic effect of PALM (Fig 
3.1).  These results give evidence that the MAC-T cells treated with PALM were in a state of ER 
stress.  Oxidative stress, measured by TBARS, was not altered by PALM (P = 0.32).  This was 
surprising, as it has been documented that PALM increases intercellular reactive oxygen species 
(ROS) production (Nakamura et al., 2009; Yuzefovych et al., 2010).  There has been some work 
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indicating that SS may have antioxidant effects (Sagone and Husney, 1987; Haynes et al., 1993); 
however, TBARS was only decreased in the presence of SS and OLEIC in combination (P < 
0.01; Fig 3.1). 
 Experiment 2 
Palmitate is a common saturated fatty acid and plays a role in creating long chain fatty 
acids and sphingolipids.  Palmitate can be taken up by the cell and converted to CER (Chavez 
and Summers, 2012).  CER are a central part of sphingolipid metabolism and are generated in 
response to stress stimuli (Hannun and Obeid, 2008; Chavez and Summers, 2012).  CER can 
induce and exacerbate ER and mitochondrial stress (Chavez and Summers, 2012).  To determine 
if PALM-induced ER stress in MAC-T cells was due to CER synthesis or PALM itself, cells 
were treated with myriocin (MY), a compound that prevents the conversion of PALM to CER 
(Chavez and Summers, 2012).  Treatment with MY mitigated the PALM effect by reducing 
mRNA abundance of total XBP-1, indicating that ER stress induced by PALM was due, at least 
in part, to CER synthesis (Fig. 3.2).  MY treatment did not completely eliminate the PALM 
effect, so it is possible that PALM also induced ER stress through a CER-independent pathway.  
Conversely, MY in combination with PALM increased mRNA abundance of CHOP (Fig. 3.2).  
There has been some evidence that MY induced apoptosis in other cell types (Chen et al., 1999; 
Furuya et al., 2002).  It is therefore possible that MY promoted apoptosis in MAC-T cells when 
the cells underwent CER-independent ER stress. 
 Experiment 3 
The results from the first two experiments were only collected at one time point (24 h).  
The third experiment was designed to monitor changes in mRNA abundance that occurred prior 
to the 24 h time point.  Interestingly, most of the large shifts in mRNA abundance of the target 
genes started to occur after 12 h of incubation (Fig. 3.3).  PALM+SS had the highest mRNA 
abundance of total XBP-1 over the entire experiement (P < 0.02).  The percent of XBP-1s 
exceeded 50% of total XBP-1 with treatment of PALM alone at 12h before falling to 12% at 24h.  
This confirms that PALM was again able to induce ER stress in the MAC-T cells.  Treatment 
with SS increased the percent of XBP-1s by 7% over CON (22% v. 29%; P = 0.02).  Activating 
transcription factor 3 (ATF3) was not affected by treatment, but was increased in all treatments 
over time (time: P < 0.01), and with PALM and PALM+SS treatments having a higher numeric 
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value at 24h.  Activated by cell stress, ATF3 is also involved in the JNK pathway, which 
stimulates inflammatory signaling (Chen et al., 1996, Zhang et al., 2001).   
The mRNA abundance of the inflammatory cytokines tumor necrosis factor alpha (TNFa) 
and interleukin-1 beta (IL-1B) was measured.  Abundance of TNFa spiked at the 12h time point 
for PALM and PALM+SS treatments, with SS treatment causing a steady increase in mRNA 
abundance over time (all interactions P < 0.01; Fig. 3.3).  PALM increased IL-1B over time (P < 
0.001), with PALM+SS closely paralleling the trajectory of mRNA abundance over time, 
indicating that SS was unable to mitigate the effect of PALM on the cells.  Since ER stress and 
inflammatory pathways are closely linked, cells with PALM-induced ER stress had higher 
abundance of inflammatory cytokines.  It is interesting that SS, an anti-inflammatory agent, did 
not decrease the inflammatory cytokine abundance in stressed cells. 
The apoptotic mediator CHOP mRNA abundance was increased with PALM (P < 0.01; 
Fig. 3.3).  There have been some reports of SS inducing apoptosis in some cell types (Schwenger 
et al., 1997; Tsutsumi et al., 2004).  Schwenger and colleagues (1997) identified that SS induces 
apoptosis through mitogen-activated protein kinase (MAPK) p38.  ER stress activates many 
MAPK pathways including p38 and JNK.  The activation of p38 MAPK phosphorylates (and 
activates) CHOP, leading to apoptosis (Cuadrado and Nebreda 2010; Darling and Cook, 2014).  
In this study, it is interesting to note that SS by itself did not have an effect on CHOP, but 
exhibited numerically higher mRNA abundance of CHOP when combined with PALM.   
Overall, SS was unable to mitigate the ER stress induced by PALM, and in some cases, 
such as total XBP-1, it exacerbated the PALM effect (PALM x SS: P < 0.001).  SS by itself had 
little effect on UPR transcripts; however in cells that are stressed, SS either failed to alleviate the 
stress or exacerbated it.  An increase in XBP-1 and XBP-1s in PALM+SS cells indicates that the 
UPR was initiated to attempt to restore homeostasis.  While SS may be assisting the cells to 
resolve the ER stress quicker, it is also possible that the effects of SS on this cell type may not be 
directly related to the UPR, but on a different component of the cell that is indirectly related to 
the UPR.  For instance, SS may alter mitochondrial function, which does not have a direct role in 
ER stress; however the mitochondria may release reactive oxygen species (ROS), which can 
stimulate ER stress.  There has been much speculation as to what mode(s) of action SS has on a 
cell, but results vary depending on the cell type, environment, and dose of SS (Amann and 
Peskar, 2002).    
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H&E staining of the cells from the 24 h time point is shown in Fig. 3.4.  A visual 
assessment of the cells show that the SS-treated cells seem swollen compared to their CON 
counterparts.  Both the PALM and PALM+SS treatments had fewer living cells, of which most 
are distended and misshapen.    
 Experiment 4 
Endoplasmic reticulum stress can lead to increased production of reactive oxygen species 
(ROS).  The ER stores large amounts of calcium.  An accumulation of misfolded and unfolded 
proteins can cause this calcium to leak into the cytosol of the cell and concentrate in the matrix 
of the mitochondria (Zhang and Kaufman, 2008).  This causes a depolarization of the 
mitochondrial membrane and leads to a disruption of electron transport and an increase of ROS 
production and subsequent oxidative stress, which can then go and further stimulate and 
exacerbate ER stress (Zhang and Kaufman, 2008).  A TBARS assay for intracellular reactive 
oxygen metabolites was performed in experiment one, however this experiment was run to 
measure extracellular ROS levels by performing a newly developed assay that measures ROS 
levels in the medium (Uy et al., 2011). 
This experiment was performed both with and without bovine serum albumin (BSA).  
Serum albumin has been shown to exhibit antioxidant properties and has a high binding affinity 
for long chain fatty acids (Roche et al., 2008), so the objective of this experiment was to 
determine if the common practice of including BSA in the cell medium had an effect on ROS 
assay results. 
Surprisingly, PALM treated cells had lower extracellular ROS concentrations measured 
by the acridan lumingen PS-3 assay than CON and SS treated cells regardless of the presence of 
BSA (P < 0.001 for BSA and no BSA; Fig. 3.5).  SS did not alter the PALM effect with or 
without BSA (P = 0.57).  SS by itself lowered ROS concentrations only in the presence of BSA 
(P < 0.001).  The presence of BSA only affected ROS levels in the SS treatment.  There has been 
some debate as to whether SS has antioxidant properties (Amann and Peskar, 2002; Rainsford, 
2004).  These results indicate that SS had no extracellular antioxidant effect when BSA was not 
present.  The creators of this assay stated that they have not identified which reactive oxygen 
species were measured by this assay (Uy et al., 2011), so it is difficult to determine the exact 
mechanisms that SS and BSA were influencing. 
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The low ROS concentrations in the PALM treated cells may be because at 180 minutes of 
incubation, PALM treatment may not have yet caused enough ER stress to elicit ROS release.  In 
the time-dependent study (experiment 3), changes in ER stress markers were not seen until after 
6-12 h of incubation.  The results from the previous experiments already indicated that SS does 
not prevent or alter the responses to PALM, so it is not surprising that the SS+PALM treatment 
resulted in ROS concentrations similar to PALM. 
To validate the unexpected ROS results obtained in the MAC-T cells, the experiement 
was repeated in HepG2 cells.  In this case, extracellular ROS was measured after 24h of 
incubation.  Without BSA, ROS concentrations in SS treated cells were about two-fold higher 
than CON (P < 0.001; Fig. 3.6).  The ROS concentrations in the PALM and PALM+SS treated 
cells were similar with and without BSA (26.3 ± 2.1 vs. 25.5 ± 2.1 and 25.8 ± 2.1 vs. 24.5 ± 2.1 
respectively).  The presence of BSA reduced the concentration of ROS in CON media by half 
(14.2 ± 2.1 vs. 30.7 ± 2.1; P < 0.001).  The apparent antioxidant properties of BSA could account 
for why SS ROS levels were much higher without BSA than with BSA. 
There has been some work that has documented increased ROS production with SS 
treatment (Chung et al., 2003; Battaglia et al., 2005).  It is believed that the reason for this 
increase in ROS production was due to SS compromising mitochondrial function by altering 
mitochondrial membrane potential (Chung et al., 2003).  While this may be a factor contributing 
to higher ROS levels in SS-treated cells, it is interesting to note that the cells that were stressed 
with PALM, which presumably interrupted mitochondrial function by altering the electron 
transport system, had lower ROS, and that PALM seemed to protect the cells in the PALM+SS 
treatment from the SS compromising mitochondrial integrity. 
 Conclusion 
Palmitate induces ER stress at least in part by driving ceramide synthesis.  Sodium 
salicylate did not mitigate the PALM effects, and in some incidences, exacerbated the response.  
The concentration of extracellular ROS was altered with the inclusion of BSA, likely due to its 
antioxidant properties.  It is important to note that ROS assay results can be altered by the 
inclusion of serum albumin, which is commonly used in cell culture media.  Overall, SS seems to 
increase the UPR transcript genes when cells are  undergoing ER stress, as well as increasing 
apoptosis in stressed cells to contain the amount of unfolded and misfolded proteins that could be 
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released and damage other cells and the host.  SS treated cells had higher ROS levels (without 
BSA) than PALM in the HepG2 cells.  The same response was not seen in the MAC-T cells, 
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2 Forward primer (5'-3') 
Reverse primer (5' -3') 
RPS9  DT860044.1  GAACAAACGTGAGGTCTGGAGG 
   
ATTACCTTCGAACAGACGCCG 
RPS15 NM_001024541.2 GGCGGAAGTGGAACAGAAGA 
   
GTAGCTGGTCGAGGTCTACG 
CHOP NM_001078163.1 CAAACAGGAAATCGAGCGCC 
   
TGGCCTGAAATGGAAGTGCT 
ATF3  NM_001046193.2 GAGTCCAGCTTCCAAAGGCT 
   
ATCACGTGGCTTCAAATGCG 
TNFα  NM_173966.1  AAGTAACAAGCCGGTAGCCCA 
   
CTTCCAGCTTCACACCGTTG 
IL-1B  NM_174093.1 GCCAACCTTCATTGCCCAGGTTT 
   
CAGGTACGGTTGCCATGGCTGT 
XBP-1 NM_001271737 TTGTCACCCCTCCAGAACATC 
   
TCCAAGTTGAACAGAATGCCC 
XBP-1s NM_001271738 TGCTGAGTCCGCAGCAGG 
      CATCAGAGTCCATGGGGAGA 
1
RPS9, ribosomal protein subunit 9; RPS15, ribosomal protein subunit 15; CHOP,
 
CCAAT/enhancer-binding protein homologous protein; ATF3, activating transcript factor 3; 
TNFa, tumor necrosis factor alpha; IL-1B, interleukin-1 beta; XBP-1, xbox binding protein 1; 
XBP-1s, spliced XBP-1 (active form). 
2




Figure 3.1 Effect of SS, PALM, and OLEIC  
 
 
Panel A: PALM, but not SS or OLEIC, altered mRNA abundance of XBP-1 (P < 0.001 and P > 0.82 respectively).  Neither SS or 
OLEIC mitigated the PALM effect (P > 0.15).  Panel B: PALM treatment increased XBP-1s (P < 0.001), while SS and OLEIC did not 
(P > 0.13).  Effect of PALM was not altered by SS or OLEIC (P > 0.15).  Panel C: SS and OLEIC did not affect CHOP abundance (P 
> 0.33) or alter the PALM effect (P > 0.12).  Panel D: PALM had no effect on TBARS (P = 0.33).  The SS and OLEIC effect (P < 




Figure 3.2 MY alters PALM effect   
 
 
Panel A: MY, a CER synthesis inhibitor, decreases XBP-1 in the presence of PALM.  Panel B: 
MY exacerbates the PALM effect on CHOP mRNA abundance.
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Figure 3.3 MAC-T cells response to PALM and SS over time   
 
 
PALM increases UPR mediators and inflammatory cytokines (A-F).  SS does not alter (C, D, E, F) and in some cases exacerbates the 




Figure 3.4 Histochemical Staining of MAC-T cells 
 
 
Hematoxylin and eosin (H&E) staining of MAC-T cells.  Cells treated with SS seem to be 
swollen and distended.  In the presence of PALM, there are few living cells, and those that are 
alive are misshapen.  Cells in the presence of PALM+SS are also misshapen. 
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Figure 3.5 MAC-T cell extracellular ROS assay   
 
 
PALM decreased extracellular ROS, and SS did not alter the PALM effect regardless of the 
presence of BSA.  SS affected ROS levels only in the presence of BSA. 
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Figure 3.6 HepG2 cell extracellular ROS assay   
 
 
PALM and SS effects on ROS were altered by BSA. 
